SCHEDULE: Biotechnology Value Fund Boosts Kura Oncology Stake

Biotechnology Value Fund and its affiliates report a 9.99% passive stake in Kura Oncology, Inc., holding 8,677,018 common shares.

Summary

• Biotechnology Value Fund L.P. and its affiliated entities (the "Reporting Persons") have filed an Amendment No. 1 to their Schedule 13G for Kura Oncology, Inc.
• The Reporting Persons collectively beneficially own 8,677,018 shares of Kura Oncology, Inc. Common Stock.
• This aggregate ownership represents 9.99% of the outstanding class of securities.
• The ownership calculation is based on 86,797,185 shares outstanding as of August 1, 2025, as reported in Kura Oncology's Quarterly Report on Form 10-Q, plus 59,856 shares underlying exercisable Pre-Funded Warrants.
• The Reporting Persons also hold Pre-Funded Warrants exercisable for an aggregate of 840,585 shares, but their exercise is limited by a 9.99% blocker, allowing only 59,856 shares to be exercised as of September 30, 2025.
• The filing certifies that the securities were not acquired for the purpose of changing or influencing control of Kura Oncology, Inc.

Sentiment

Score: 7

Explanation: The disclosure of a significant passive stake by a specialized biotechnology fund is generally viewed positively, indicating institutional confidence in the company.

Positives

• Significant institutional investment from a specialized biotechnology fund, indicating confidence in Kura Oncology, Inc.'s prospects.
• The fund's aggregate ownership of 9.99% suggests a substantial, long-term passive interest in the company.

Negatives

• The 9.99% Pre-Funded Warrants Blocker limits the immediate exercise of a large portion of the held warrants (840,585 total warrants, but only 59,856 exercisable due to the blocker), potentially restricting the fund's ability to increase its voting power beyond the stated percentage without further disclosures or actions.

Risks

• No specific risks related to Kura Oncology, Inc.'s operations or financial health are disclosed in this Schedule 13G filing, as it pertains to beneficial ownership by an investor.

Future Outlook

This filing does not contain forward-looking statements or guidance from Kura Oncology, Inc. It is a disclosure of beneficial ownership by an external investor.

Industry Context

The investment by Biotechnology Value Fund, a specialized fund, highlights continued institutional interest in the biotechnology sector, particularly in companies like Kura Oncology, Inc. This type of passive investment often signals a belief in the long-term potential of the company's pipeline or market position within the competitive biotech landscape.

Stakeholder Impact

• Shareholders may view the significant passive stake by a specialized institutional investor as a positive signal, potentially increasing confidence in the company's long-term prospects.
• Management will be aware of a large passive institutional holder, which may subtly influence strategic considerations, though the filing explicitly states no intent to influence control.

Key Dates

Keywords

Kura Oncology, Inc., Biotechnology Value Fund, BVF, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, Biotechnology, Healthcare, Equity Stake